CSIMarket
 
Catheter Precision Inc   (NYSE: VTAK)
Other Ticker:  
 
 
Price: $0.3596 $-0.01 -3.385%
Day's High: $0.37 Week Perf: -6.84 %
Day's Low: $ 0.33 30 Day Perf: -18.27 %
Volume (M): 343 52 Wk High: $ 8.40
Volume (M$): $ 123 52 Wk Avg: $2.56
Open: $0.37 52 Wk Low: $0.31



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 2
 Employees 50
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -12
 Cash Flow (TTM) (Millions $) -4
 Capital Exp. (TTM) (Millions $) 0

Catheter Precision Inc
Catheter Precision Inc is a medical device manufacturing company that specializes in the production of catheters. They are focused on developing high-quality, innovative catheter solutions for use in various medical procedures. Catheter Precision Inc aims to provide healthcare professionals with advanced products that improve patient outcomes, enhance efficiency, and ensure patient safety. They prioritize precision in their manufacturing processes to deliver reliable and accurate catheters that meet the needs of their customers.


   Company Address: 1670 Highway 160 West Fort Mill 29708 SC
   Company Phone Number: 691-2000   Stock Exchange / Ticker: NYSE VTAK


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BAX   -1.06%    
BDX   -2.2%    
BSX      0% 
EW        6.8% 
MDT        1.99% 
SYK   -1.13%    
• View Complete Report
   



Catheter Precision Inc

VTAK Faces Revenue Decline in Q1 2024 Despite Improvement in Net Deficit

Investors in Catheter Precision Inc (VTAK) may be feeling cautious following the company's recent financial results for the January to March 31, 2024 reporting period. The company reported a loss of $-0.36 per share, a significant improvement from the $-24.65 loss per share reported a year ago but a decline from the previous reporting period's breakeven results. Revenue also decreased by -3.529% year-over-year and tumbled by -35.938% sequentially.
This drop in revenue is concerning, especially when compared to the broader Medical Equipment & Supplies industry which has seen revenue improvements. However, it is worth noting that Catheter Precision Inc reported a net deficit of $-2.675 million for the period, a significant improvement from the $-66.400 million deficit reported in the same period last year.

Catheter Precision Inc

Catheter Precision Inc Surpasses Expectations with Unprecedented Results as of Dec 31 2023



The stock market is a dynamic and ever-changing landscape, where investors constantly seek opportunities to capitalize on promising companies. In the Medical Equipment & Supplies sector, two companies have caught the attention of investors with their noteworthy performances ? VTAK and Catheter Precision Inc.
VTAK's Break-Even Achievement:
During the financial fourth quarter of 2023, VTAK managed to reach break-even at $0.00 per share, a significant improvement from the previous year's loss per share of $-0.25. Moreover, this achievement marked a decrease from the prior quarter's loss per share of $-0.28. The revenue for the quarter witnessed substantial growth, reaching $0.13 million, compared to $0.00 million in the comparable quarter the previous year.

Catheter Precision Inc

Catheter Precision Inc's Q3 Report Reveals Significant Revenue Growth, Patient Costs Management



Investors are closely following the third-quarter earnings season to assess the financial performance of various companies. In this regard, Catheter Precision Inc has provided its report, which shows a significant improvement compared to the previous year. While the company has reported a net loss, it is worth noting that VTAK, another competitor in the sector, has achieved commendable revenue during the same period. However, recent market trends and the company's shares performance raise concerns about its future prospects.
Catheter Precision Inc's Q3 2023 Earnings Season Results:
During the third quarter of the 2023 earnings season, Catheter Precision Inc announced a net loss of $-1.927 million, representing a substantial reduction compared to a deficit of $-4.763 million in the corresponding quarter of the previous year. This positive development suggests that the company has made strides in cost management and efficiency improvements.

Catheter Precision Inc

Breaking News: Catheter Precision Inc Unveils Mind-Blowing 1820% Surge in Revenue, Surpassing Expectations in Record Fiscal Quarter

Analyzing VTAK's Financial Results and Projecting Future Impact
VTAK, a company operating in the Medical Equipment & Supplies sector, recently released its financial results for the most recent fiscal period, revealing some intriguing findings. The top-line revenue for the company skyrocketed by an astonishing 1820% year on year, reaching a value of $0.10 million. This impressive growth outpaced the majority of VTAK's competitors in the same industry, who reported an average top-line advance of 4.79% for the second quarter of 2023 compared to the same period in 2022.
While the revenue growth is undoubtedly a positive sign for VTAK, there are concerns to be addressed as well. The deficit for the company widened to $-0.29 million, indicating that expenses were outpacing revenue growth. VTAK needs to carefully manage its costs to ensure profitability in the future.







Catheter Precision Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com